The Tumor Microenvironment of Bladder Cancer

Hatogai, Ken; Sweis, Randy F.

doi:10.1007/978-3-030-59038-3_17

Cited by 28 publications

(23 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bladder cancer is one of the most malignant diseases of the urinary system. It can be classified into three categories based on the progression status: non-muscle invasive bladder cancer, muscle invasive bladder cancer, and metastatic bladder cancer [ 184 ]. Recently, immune therapy targeting the PD-1/L1 checkpoint pathway was found to be effective for metastatic bladder cancers, while it was also reported that the bladder TME is able to promote and inhibit the antitumor immune response.…”

Section: Bioprinting To Mimic the Urological Tmementioning

confidence: 99%

The application of 3D bioprinting in urological diseases

Han

Huang

et al. 2022

Materials Today Bio

View full text Add to dashboard Cite

Section: Bioprinting To Mimic the Urological Tmementioning

confidence: 99%

The application of 3D bioprinting in urological diseases

Han

Huang

et al. 2022

Materials Today Bio

View full text Add to dashboard Cite

“…In order to escape the anti-tumor immune response, tumor cells could secrete immunosuppressive and anti-apoptotic factors or recruit suppressive immune cells to generate a highly immunosuppressive microenvironment through different mechanisms [ 42 , 43 ]. In BC TME, accumulated immunosuppressive cells (e.g., myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs) and regulatory T cells (T regs) and evaluated expression of immune checkpoints (e.g., CTLA-4 and PD-1) were reported to induce immune evasion of tumor cells [ 44 , 45 ]. Therefore, we evaluated the landscape of immune cell infiltration for the high and low ARPS risk groups by ESTIMATE, Timer, MCPcounter and xCell algorithm, which revealed that a higher degree of immune cell infiltration and greater abundance of immunosuppressive cells including Tregs, TAMs and MDSCs were found in the high ARPS risk group than these in the low ARPS risk group.…”

Section: Discussionmentioning

confidence: 99%

Identification and Validation of an Annexin-Related Prognostic Signature and Therapeutic Targets for Bladder Cancer: Integrative Analysis

Yao

Wang

et al. 2022

Biology

View full text Add to dashboard Cite

Abnormal expression and dysfunction of Annexins (ANXA1-11, 13) have been widely found in several types of cancer. However, the expression pattern and prognostic value of Annexins in bladder cancer (BC) are currently still unknown. In this study, survival analysis by our in-house OSblca web server revealed that high ANXA1/2/3/5/6 expression was significantly associated with poor overall survival (OS) in BC patients, while higher ANXA11 was associated with increased OS. Through Oncomine and GEPIA2 database analysis, we found that ANXA2/3/4/13 were up-regulated, whereas ANXA1/5/6 were down-regulated in BC compared with normal bladder tissues. Further LASSO analysis built an Annexin-Related Prognostic Signature (ARPS, including four members ANXA1/5/6/10) in the TCGA BC cohort and validated it in three independent GEO BC cohorts (GSE31684, GSE32548, GSE48075). Multivariate COX analysis demonstrated that ARPS is an independent prognostic signature for BC. Moreover, GSEA results showed that immune-related pathways, such as epithelial–mesenchymal transition and IL6/JAK/STAT3 signaling were enriched in the high ARPS risk groups, while the low ARPS risk group mainly regulated metabolism-related processes, such as adipogenesis and bile acid metabolism. In conclusion, our study comprehensively analyzed the mRNA expression and prognosis of Annexin family members in BC, constructed an Annexin-related prognostic signature using LASSO and COX regression, and validated it in four independent BC cohorts, which might help to improve clinical outcomes of BC patients, offer insights into the underlying molecular mechanisms of BC development and suggest potential therapeutic targets for BC.

show abstract

“…Effects of SCFAs on the tumour microenvironment. SCFAs can boost cellular metabolism and memory potential in CD8 + T cells [99], which may mean that SCFAs can promote a favourable tumour microenvironment in bladder cancer, in which T-cell inflamed tumours [100] with increased FOXP3 + Treg infiltration [101] have been associated with improved patient survival. Their anti-inflammatory properties also point them to a potential treatment for IR-induced RE.…”

Section: Effects Of Scfas On Cancer Cells An Interesting Inconsistenc...mentioning

confidence: 99%

Exploiting dietary fibre and the gut microbiota in pelvic radiotherapy patients

et al. 2022

View full text Add to dashboard Cite

With an ageing population, there is an urgent need to find alternatives to current standard-of-care chemoradiation schedules in the treatment of pelvic malignancies. The gut microbiota may be exploitable, having shown a valuable role in improving patient outcomes in anticancer immunotherapy. These bacteria feed on dietary fibres, which reach the large intestine intact, resulting in the production of beneficial metabolites, including short-chain fatty acids. The gut microbiota can impact radiotherapy (RT) treatment responses and itself be altered by the radiation. Evidence is emerging that manipulation of the gut microbiota by dietary fibre supplementation can improve tumour responses and reduce normal tissue side effects following RT, although data on tumour response are limited to date. Both may be mediated by immune and non-immune effects of gut microbiota and their metabolites. Alternative approaches include use of probiotics and faecal microbiota transplantation (FMT). Current evidence will be reviewed regarding the use of dietary fibre interventions and gut microbiota modification in improving outcomes for pelvic RT patients. However, data regarding baseline (pre-RT) gut microbiota of RT patients and timing of dietary fibre manipulation (before or during RT) is limited, heterogenous and inconclusive, thus more robust clinical studies are required before these strategies can be applied clinically.

show abstract

The Tumor Microenvironment of Bladder Cancer

Cited by 28 publications

References 115 publications

The application of 3D bioprinting in urological diseases

The application of 3D bioprinting in urological diseases

Identification and Validation of an Annexin-Related Prognostic Signature and Therapeutic Targets for Bladder Cancer: Integrative Analysis

Exploiting dietary fibre and the gut microbiota in pelvic radiotherapy patients

Contact Info

Product

Resources

About